ClinicalTrials.gg

Program

Mesenchymal Stem Cells (MSCs)

Its studies are mostly in Proctitis · Rectal Fistula, led by Jiangsu Topcel-KH Pharmaceutical.

Furthest: phase 2, since May 23, 20243 company-led studies, 3 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu Topcel-KH Pharmaceutical33 open or runningphase 2since May 23, 2024May 9, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 9, 2024First study: phase 1 study in Rectal FistulaFirst studyNCT06429241 · 8 planned · China
  2. May 23, 2024Phase 2 study in Chronic Radiation ProctitisNCT06438809 · 24 planned · China
  3. Apr 7, 2025Phase 1 study in Radiation ProctitisNCT06925607 · 6 planned

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06925607Radiation Proctitis1Not yet recruitingMar 20266
NCT06438809Chronic Radiation Proctitis · China2RecruitingMay 202524
NCT06429241Rectal Fistula · China1RecruitingNov 20248

How it is read

Names in the registry

  • “Mesenchymal Stem Cells (MSCs)”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.